ANNXHealthcare · BiotechnologyThe 10 Wall Street analysts covering Annexon, Inc. hold a median 12-month price target of $12 — +126.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Annexon, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (73): The shares have been drifting up relative to others.
Quality (25): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ANNX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +126.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Citizens | Upgrade | Market Perform | — |
| 21 July 2026 | Citizens | Initiates | Market Underperform | $3.00 |
| 15 July 2026 | Needham | Maintains | Buy | $11 → $25 |
| 12 May 2026 | Goldman Sachs | Initiates | Neutral | — |
| 20 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 23 Dec 2025 | Chardan Capital | Initiates | Buy | — |
| 2 Dec 2025 | Clear Street | Initiates | Buy | — |
| 19 Nov 2025 | Wells Fargo | Maintains | Overweight | — |
| 15 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 May 2025 | Needham | Maintains | Buy | — |
| 4 Mar 2025 | Needham | Reiterates | Buy | — |
| 17 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | Needham | Reiterates | Buy | — |
| 9 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 13 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2024 | Needham | Reiterates | Buy | — |
| 5 June 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANNX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 22% of US stocks
Cheaper than 77% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 12% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Annexon, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Annexon, Inc. held its Q2 2026 earnings conference call, during which management discussed the company's financial results and business developments for the quarter.
Why it matters — Earnings calls provide investors with official updates on financial performance, operational progress, and management's outlook.
Annexon expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy by adding an independent 24-month dual primary endpoint alongside the existing 15-month primary endpoint. The company remains confident in a planned Q4 assessment of the 15-month endpoint while seeking longer-term efficacy data for a potential product label.
Why it matters — A watcher would care because the trial expansion signals Annexon is positioning vonaprument for a more robust efficacy data package that could influence future regulatory labeling for the geographic atrophy treatment.
Annexon reported its second quarter 2026 financial results along with business updates and anticipated milestones. The company highlighted rapid, positive clinical outcomes in the GBS FORWARD study that reinforce the consistency and reproducibility of the tanruprubart treatment effect seen in Phase 3 and real-world evidence studies, with a BLA submission expected in Q4 2026.
Why it matters — The positive FORWARD study results and the expected Q4 2026 BLA submission signal meaningful clinical progress for tanruprubart, a key advancement in Annexon's pipeline.
Annexon has added a Month 24 dual primary endpoint to complement the Month 15 primary endpoint in its Phase 3 ARCHER II trial of vonaprument for geographic atrophy, and has launched an open-label extension study of the treatment. The dual primary endpoint strategy allows the trial to show success in protecting against vision loss at either timepoint.
Why it matters — This expands the flexibility and long-term data collection for Annexon's key Phase 3 geographic atrophy program, which is central to its clinical pipeline.
Annexon reported that the first U.S. and European patient cohort of the GBS FORWARD study showed rapid, positive clinical responses in all tanruprubart-treated patients within one week. The company said the early outcomes reinforce the consistency and reproducibility of the treatment effect previously demonstrated in Phase 3 and real-world evidence studies.
Why it matters — An ANNX watcher would care because this cohort data supports the consistency and reproducibility of tanruprubart's clinical effect in GBS across further study settings.
The 10 Wall Street analysts covering Annexon, Inc. have a median 12-month price target of $12, with estimates ranging from $7 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Annexon, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Annexon, Inc. 38 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Annexon, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (73 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +126.8% from the last close, and Ticker Nerd's factor model ranks Annexon, Inc. 38 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Annexon, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $27 over the next 12 months.
Annexon, Inc. returned +122.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for autoimmune, neurodegenerative, and ophthalmic diseases.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript". Annexon, Inc. held its Q2 2026 earnings conference call, during which management discussed the company's financial results and business developments for the quarter.
Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for autoimmune, neurodegenerative, and ophthalmic diseases. The company advances a pipeline of product candidates designed to target the classical complement pathway, a key component of the immune system implicated in these debilitating conditions. Its lead programs address unmet needs in areas such as Guillain-Barré syndrome, Huntington's disease, and geographic atrophy associated with age-related macular degeneration. Annexon, Inc. emphasizes innovative monoclonal antibodies that modulate complement activity to halt disease progression and preserve neurological and retinal function. Operating within the biotechnology industry of the healthcare sector, the company conducts clinical trials to evaluate the safety, efficacy, and potential of its therapies in patient populations. Founded in 2011 and headquartered in Brisbane, California, Annexon, Inc. plays a role in advancing treatments for complement-mediated disorders through rigorous scientific research and development efforts.
CEO Mr. Douglas E. Love Esq., J.D. · 92 employees · United States · https://www.annexonbio.com